Moleculin Biotech Ownership

MBRX
 Stock
  

USD 1.46  0.07  5.04%   

Some institutional investors establish a significant position in stocks such as Moleculin Biotech in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Moleculin Biotech, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Additionally, see Stocks Correlation.
  
Refresh
Moleculin Biotech Book Value per Share is fairly stable at the moment as compared to the past year. Moleculin Biotech reported Book Value per Share of 2.94 in 2021. Current Ratio is likely to rise to 21.60 in 2022, whereas EBITDA Margin is likely to drop (7.93)  in 2022.
Moleculin Biotech maintains a total of twenty-eight million five hundred eighty thousand outstanding shares. Roughly 83.0 % of Moleculin Biotech outstanding shares are held by regular investors with 2.15 pct. owned by insiders and only 14.67 % by institutional investors. Please note that no matter how much assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Moleculin Stock Ownership Analysis

About 15.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.51. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Moleculin Biotech recorded a loss per share of 0.7. The entity had not issued any dividends in recent years. The firm had a split on the 1st of February 2021. Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. To find out more about Moleculin Biotech CS contact the company at 713 300 5160 or learn more at https://www.moleculin.com.
Besides selling stocks to institutional investors, Moleculin Biotech also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Moleculin Biotech's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Moleculin Biotech's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Moleculin Biotech Quarterly Share Based Compensation

527,000

Share
Roughly 2.0% of Moleculin Biotech CS are currently held by insiders. Unlike Moleculin Biotech's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Moleculin Biotech's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%.

Moleculin Biotech SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Moleculin Biotech prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Moleculin Biotech investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Moleculin Biotech specific information freely available to individual and institutional investors to make a timely investment decision.
16th of June 2022
Financial Statements and Exhibits. Regulation FD Disclosure
View
31st of May 2022
Submission of Matters to a Vote of Security Holders
View

Moleculin Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Moleculin Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Moleculin Biotech CS backward and forwards among themselves. Moleculin Biotech's institutional investor refers to the entity that pools money to purchase Moleculin Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Vanguard Group IncCommon Shares1.1 M1.9 M
Sio Capital Management LlcCommon SharesM1.9 M
Blackrock IncCommon Shares265.3 K472 K
Geode Capital Management LlcCommon Shares245.6 K437 K
State Street CorpCommon Shares71.4 K127 K
Renaissance Technologies LlcCommon Shares59.9 K107 K
Sigma Planning CorpCommon Shares57.5 K102 K
Note, although Moleculin Biotech's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Moleculin Biotech Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Moleculin Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Moleculin Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Moleculin Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Moleculin Biotech Investors Sentiment

The influence of Moleculin Biotech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Moleculin. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Moleculin Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Moleculin Biotech's short interest history, or implied volatility extrapolated from Moleculin Biotech options trading.

Current Sentiment - MBRX

Moleculin Biotech Investor Sentiment

Most of Macroaxis users are now bullish on Moleculin Biotech CS. What is your trading attitude regarding investing in Moleculin Biotech CS? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moleculin Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
41.7 M
Return On Assets
-0.17
Return On Equity
-0.23
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.